Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit

• Status: Terminated
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

To assess the effect of fesoterodine 8 mg as compared to solifenacin 10 mg on colonic transit.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pfizer
• Treatments: Fesoterodine; Solifenacin Succinate

Criteria

Inclusion Criteria:

• Healthy female subjects

Exclusion Criteria:

• Evidence or history of clinically significant findings at screening